R&D Paradigm Shift and Billion-Dollar Biologics

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 161-199

  Maggon, Krishan ^a  

^a Pharma Biotech R and D Consultant   (Switzerland)

Author keywords

Major R D and clinical trial success; Public private partnerships; R D paradigm shift and billion dollar biologics

Indexed keywords

EID: 84889834688     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch1e     Document Type: Chapter

References (73)

1. Ernst & Young. (2005 & 2006). Global Biotech Report and Global Pharmaceutical Trends.
2. Levinson AD (2005). What distinguishes biotech from big pharma? Global Industry Perspectives.
3. Bains & Company Reports. Rebuilding Big Pharma's Business Model. (2003) Addressing the Innovation Divide: Imbalanced innovation (2004).
4. Boston Consultancy Group. The gentle art of licensing. (2004) Rising to the productivity challenge. (2004).
5. FDA. (2004, 2006). Innovation or stagnation: Challenge and opportunity on the critical path to new medicinal products. CDER (2004). Report to the nation. Improving public health through human drugs.
6. Cockburn I M (2004). The changing structure of the pharmaceutical industry, Health Affairs. 23:10-22.
7. Ng R (2003). Drugs: From Discovery to Approval. John Wiley, New York, pp. 368.
8. Pfizer (2005). Annual Report. Available: www.pfizer.com.
9. Trombetta B (2005). Industry Audit, Pharm. Exec. 10:68-80.
10. Sellers L J (2004). Top 50 Pharma Companies. Pharm. Exec. 24:60-70. Available: www.pharmexec.com.
11. Parker M G, Amar D (2005). Building blockbusters. Pharm. Exec. 10:82-88.
12. Forbes (2004). Potential blockbuster drugs. Available: www.forbes.com/2003/10/08/cz_fmc_1008sf.html.
13. IMS Top Line Global Industry Data (2005). Available: www.imshealth.com,http://www.ims-global.com/insight/insight.htm.
14. Reuters Health. Reports (2004). The Pharmaceutical Market Outlook to 2010. Available: http://www.reutersbusinessinsight.com/content/rbhc0091t.pdf.
15. Datamonitor Potential blockbuster drugs (2004). Available: www.datamonitor.com.
16. Maggon K (2003). The ten billion dollar molecule. Pharm. Exec. 23:60-68.
17. Maggon K (2005). Best Selling Human Medicines 2002-2004. Drug Disc. Today. 10:738-742.
18. Maggon K (2004). The future of the research based pharmaceutical industry. Express Pharma. Pulse. January 29, 2004. Available: http://www.expresspharmapulse.com/20040129/oped01.shtml.
19. Maggon K (2004). Impact of Vioxx withdrawal on pharma R&D. Medicine and Biotech. com. November, 15, 2004. Available: http://www.medicineandbiotech.com/therapy.html1.html.
20. Maggon K (2002). Ups and down in drug development. Express Pharma. Pulse. Mumbai. October 3, 2002. Express Healthcare Management Mumbai, October 16, 2002. http://www.expresshealthcaremgmt.com/20021031/edit2.shtml.
21. Niazi S K (2005). Handbook of Biogeneric Therapeutic Proteins: Regulatory, Manufacturing, Testing, and Patent Issues. Taylor & Francis CRC Press, Boca Raton, F.L., p. 584.
22. Rader R A (2005). Biopharmaceutical Products in the USA and European Markets. Bioplan Associates, Rockville, M. D., p. 1234.
23. Maggon K (2004). Setting new standards about drug safety. Express Pharma. Pulse. 22 May 2004. Available: http://www.expresspharmapulse.com/20030522/edit2.shtml.
24. DiMasi J A, Hansen R W, Grabowski H G (2003). The price of innovation: New estimates for drug development costs. J. Health Econ. 22:151-185.
25. Grabowski H, Vernon J (2000). The determinants of pharmaceutical research and development expenditures. J. Evo. Econ. 10:201-215.
26. Biobusiness (2005). Sales of recombinant drugs. Available: www.i-s-b.net/business/recombinant_f.htm.
27. Danzon P M, Nicholson S, Pereira N S (2005). Productivity in pharmaceutical-biotechnology R&D: The role of experience and alliances. J. Health Econ. 24:317-339.
28. Higgins M J, Rodriguez D (2005). The outsourcing of R&D through acquisitions in the pharmaceutical industry. J. Financial Econ., In Press, Corrected Proof, Available online 2 November.
29. Schmid E F, Smith D A (2004). Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Disc. Today, 9:18-26.
30. Thomas L G (2004). Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strat. Manag. J. 25:865-886.
31. Penner-Hahn J, Shaver J M (2005). Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strat. Manag. J. 26:121-140.
32. Drews J, Ryser S (1996). Innovation deficit in the pharmaceutical industry. Drug Inform. J. 30:97-107.
33. Drews J (1998). Innovation deficit revisited: Reflections on the productivity of pharmaceutical R&D. Drug Disc. Today. 11:491-494.
34. Demain A L (2002). Prescription for an ailing pharmaceutical industry. Nature Biotechn. 20:331-334.
35. Ho R J Y, Gibaldi M (2003). Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. Wiley, New York.
36. Maggon K (2004). Rise of biologicals. Express Pharma. Pulse. February 5, 2004. Available: http://www.expresspharmapulse.com/20040205/editorial02.shtml.
37. Maggon K (2005). Biotech segment: Moving ahead of pharmaceutical industry. Express Pharma. Pulse. April 28, 2005. Available: http://www.expresspharmapulse.com/20050428/edit02.shtml.
38. Collins S W (2004). The Race to Commercialize Biotechnology: Molecules, Market and the State in Japan and the US. p. 224 Routledge, Oxford, U.K., p. 224.
39. Liossis S N C, Tsokos G C (2005). Monoclonal antibodies and fusion proteins in medicine. J. Allergy Clin. Immunol. In Press, Corrected Proof, Available online 1 September 2005.
40. Qu Z, Griffiths G L, Wegener W A, et al. (2005). Development of humanized antibodies as cancer therapeutics. Methods. 36:84-95.
41. Pavlou A K, Belsey M J (2005). The therapeutic antibodies market to 2008. Eur. J. Pharmaceut. Biopharmaceut. 59:389-396.
42. Charles S A (2005). Super Generics: A better alternative for biogenerics. Drug Disc. Today. 10:533-535.
43. Sesin C A, Bingham C O (2005). Remission in rheumatoid arthritis: Wishful thinking or clinical reality? Seminars in Arthritis and Rheumatism. 35(3):185-196.
44. Hochberg M C, Lebwohl M G, Plevy S E, et al. (2005). The benefit/risk profile of TNFBlocking agents: Findings of a consensus panel. Seminars in Arthritis and Rheumatism. 34:819-836.
45. Miossec P (2005). Therapeutic targets in rheumatoid arthritis: More to come but which one(s) to select? Drug Disc. Today: Disease Mech. 2:327-330.
46. Thomas V D, Yang F C, Kvedar J C (2005). Biologics in psoriasis: A quick reference guide. J. Amer. Acad. Dermatol. 53:346-351.
47. Gómez-Pérez F J, Rull J A (2005). Insulin therapy: Current alternatives. Arch. Med. Res. 36:258-276.
48. Gerich J E (2002). Novel insulins: Expanding options in diabetes management. American J. Med. 113:308-316.
49. Feemester R (2006). Holding their breath: Pipeline watch. Pharmceut. Exec. 26:58-62.
50. Girard M P, Cherian T, Pervikov Y, et al. (2005). A review of vaccine research and development: Human acute respiratory infections. Vaccine. 23:5708-5724.
51. Manoj S, Babiuk L A, van Drunen Littel-van den Hurk S (2004). Approaches to enhance the efficacy of DNA vaccines. Critical Reviews in Clinical Laboratory Sciences. 41:1-39.
52. Plotkin S A (2005). Vaccines: Past, present and future. Nature Med. Suppl. 11:s5-s11.
53. Nahta R, Esteva F J (2005). Herceptin: Mechanisms of action and resistance. Cancer Letters. In Press, Corrected Proof, Available online 30 March 2005.
54. Ferrara N, Hillan K J, Novotny W (2005). Bevacizumab (Avastin), A humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophy. Res. Commun. 333:328-335.
55. Erlichman C, Sargent D J (2004). New Treatment Options for Colorectal Cancer. N. Engl. J. Med. 351:391-392.
56. Silvestrelli G, Lanari A, Parnetti L, et al. (2006). Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophy siology. Mech. of Ageing and Devel. 127:148-157.
57. Lipton S A (2004). Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRX. 1:101-110.
58. Maggon K, Barik S (2004). New Drugs and treatment for respiratory syncytial virus. Rev. Molec. Virology. 14:149-168.
59. Tongren J E, Zavala F, Roos D S, et al. (2004). Malaria vaccines: If at first you don't succeed ... Trends in Parasitology. 20:604-610.
60. Girard M P, Osmanov S K, Kieny M P (2006). A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine. In Press, Corrected Proof, Available online 28 February 2006.
61. Lowrie D B (2006). DNA vaccines for therapy of tuberculosis: Where are we now? Vaccine. 24:1983-1989.
62. Okaji Y, Tsuno N H, Saito S, et al. (2006). Vaccines targeting tumour angiogenesis-A novel strategy for cancer immunotherapy. Euro. J. Surgical Oncology. In Press, Corrected Proof.
63. Maggon K (2003). Activated Protein C in treating sepsis. Express Pharma. Pulse. Mumbai February 27, 2003, Express Healthcare Management Mumbai, March 1, 2003.
64. Maggon K (2003). Risk benefit assessment of APC. Express Pharma. Pulse. Mumbai. March 6, 2003. Express Healthcare Management Mumbai, April 1, 2003.
65. Griffin J H, Fernández J A, Mosnier L O, et al. (2006). The promise of protein C. Blood Cells, Mol. Dis. In Press, Corrected Proof, Available online 7 February 2006.
66. Cacciotti J, Shew B (2006). Pharma's next top model. Pharm. Exec. 26:82-86.
67. Schrag D (2004). The price tag on progress-Chemotherapy for colorectal cancer. N. Engl. J. Med. 351:317-319.
68. Angell M (2004). The truth about drug companies. Random House, New York, p. 336.
69. Maggon K (2004). Regulatory reforms and GCP Clinical Trials with New Drugs in India. Clinical Trials. 1:1-7.
70. Gardner C, Gardner C (2004). Technology licensing to nontraditional partners: Nonprofit health product development organizations for better global health. Available: http://www.mihr.org/?q=taxonomy_menu/1/6.
71. Moran M (2005). The new landscape of neglected disease drug development. Wellcome Trust, LSE and OECD Report. Available: http://www.wellcome.ac.V.
72. Maggon K (2007). Market intelligence and pharma data mining. http://www.medicineandbiotech.com. e-Published, Feb 1, 2007.
73. Maggon K, Maggon S (2007). Overview of the pharmaceutical and biotechnology industry performance in 2006. http://www.medicineandbiotech.com. e-Published, March 1, 2007.